[ET Net News Agency, 26 February 2024] HSBC Global Research lowered the target price
for CSPC Pharma (01093) to HKD7.25 from HKD8 and maintained the "hold" rating.
The research house said the sale of key assets and volume-based procurement pressures
are major downside risks. It forecasts low-teens top/bottom-line growth in 2024-25. (RC)